Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 11/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 8/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.55 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6493029 | 1.00 | SLC6A3 (0.55) | SLC6A3SLC6A2SLC6A4PTGS2ALDH1A1 | |
| SCHEMBL6491174 | 1.00 | SLC6A3 (0.55) | SLC6A3SLC6A2SLC6A4PTGS2ALDH1A1 | |
| SCHEMBL6502878 | 1.00 | SLC6A3 (0.55) | SLC6A3SLC6A2SLC6A4PTGS2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL6501875 | 0.98 | SLC6A3 (0.54) | SLC6A3SLC6A2SLC6A4PTGS2ALDH1A1 | |
| SCHEMBL6503402 | 0.96 | SLC6A3 (0.51) | SLC6A3SLC6A2SLC6A4PTGS2ALDH1A1 | |
| SCHEMBL6501871 | 0.84 | SLC6A3 (0.51) | SLC6A3SLC6A2SLC6A4PTGS2ALDH1A1 | |
| SCHEMBL10524688 | 0.83 | SLC6A3 (0.53) | SLC6A3SLC6A2SLC6A4HSD17B10 | |
| SCHEMBL6503574 | 0.83 | SLC6A3 (0.75) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL1752157 | 0.82 | SLC6A3 (0.65) | SLC6A3SLC6A2SLC6A4PTGS2 | |
| SCHEMBL1751614 | 0.82 | SLC6A3 (0.65) | SLC6A3SLC6A2SLC6A4PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | DAISO CO., LTD. (JP) | 2005-02-17 | — | — | US | disclosed |
| EP-1472226-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-11-03 | — | — | EP | disclosed |
| WO-2003045921-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | APOB, APOL1, CTRB2 | SLC6A3 3942/4885SLC6A2 1801/4885SLC6A4 3899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.